Jingjing Schneider

Cognitive Function in a Randomized Trial of Evolocumab

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · New England Journal of Medicine · 2017 · 482 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Meletios Α. Dimopoulos, Stephen Opat, Shirley D’Sa et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Hematology, Pharmacology +11

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Meletios Α. Dimopoulos, Ramón García‐Sánz, Hui‐Peng Lee et al. · Blood Advances · 2020 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · Clinical Cardiology · 2017 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17